Malaria Treatment Market Report 2026

The malaria treatment market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to high prevalence of malaria in tropical regions, widespread use of chloroquine and artemisinin, global health initiatives like who malaria programs, increased funding for malaria research, improvements in diagnostic technologies.

The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of new antimalarial vaccines, rise in drug-resistant malaria strains, adoption of digital health monitoring systems, expansion of healthcare infrastructure in africa and asia, growth in public-private partnerships for malaria eradication. Major trends in the forecast period include rapid diagnostic technology adoption, expansion of antimalarial drug pipeline, growth of vaccine development programs, increasing awareness and preventive measures, integration of telemedicine for malaria management.

The high incidence of malaria is anticipated to drive the growth of the malaria treatment market in the coming years. Malaria is a potentially life-threatening mosquito-borne disease caused by Plasmodium parasites and is marked by recurring fever and flu-like symptoms. The increasing burden of malaria is largely attributed to factors such as poverty, limited access to healthcare services, climate change, inadequate malaria control measures, and rising drug resistance. Malaria treatment plays a critical role in effectively managing and curing infections caused by Plasmodium parasites. For example, in December 2024, according to the UK Health Security Agency, imported malaria cases in the UK reached 2,106 in 2023, representing a 26% increase compared to 2022, with England accounting for 1,977 cases and the remaining cases reported across Scotland, Wales, and Northern Ireland. Therefore, the high incidence of malaria is contributing to the growth of the malaria treatment market.

Rising healthcare expenditure is also expected to support the growth of the malaria treatment market going forward. Healthcare spending includes the total financial resources allocated to healthcare systems within a region or country. Increased spending on malaria treatment is essential for improving disease management and prevention by enabling access to timely diagnosis, antimalarial drugs, and preventive interventions. For example, in April 2025, according to the Office for National Statistics, total healthcare expenditure increased by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare expenditure as a share of GDP remained steady at 11.1% in 2024. As a result, the rise in healthcare spending is further driving the expansion of the malaria treatment market.

Companies operating in the malaria treatment market are increasingly focusing on vaccine rollouts to strengthen prevention efforts and reduce the global malaria burden. A vaccine rollout involves the large-scale distribution and administration of vaccines across targeted populations. For instance, in July 2024, Gavi launched the rollout of the R21 malaria vaccine. The R21 vaccine is expected to substantially reduce malaria cases among children under the age of five and represents a major milestone in public health initiatives aimed at lowering disease burden and mortality linked to this preventable illness.

Major companies operating in the malaria treatment market are Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Strides Pharma Science Limited, AdvaCare Pharma USA LLC, Actiza Pharmaceutical Private Limited.

Middle East and Africa was the largest region in the malaria treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the malaria treatment market by raising the cost of imported antimalarial drugs, diagnostic kits, and medical equipment, particularly affecting regions like Africa and Southeast Asia that rely heavily on imports. The prescription medications and diagnostic tests segments are most impacted due to dependency on global supply chains. While tariffs have increased production and distribution costs, they have also encouraged local manufacturing and innovation in cost-effective malaria solutions, providing an opportunity to develop domestic supply resilience.

The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malaria treatment refers to the medical interventions and procedures used to diagnose, manage, and cure malaria, a potentially life-threatening disease transmitted by mosquitoes and caused by the Plasmodium parasite.

The main components of malaria treatment include prescription medications, vaccines, diagnostic tests, and others. Prescription medications are drugs that can be obtained only with a valid prescription from a healthcare professional and are used in malaria treatment to provide controlled and targeted therapy against the infection. These medications are administered through oral, parenteral, and intravenous routes and are distributed via channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others, for use by hospitals, specialty clinics, home care settings, and other end users.

The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.